Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Prayura Kunasol"'
Autor:
Peter B Gilbert, Jean-Louis Excler, Georgia D Tomaras, Lindsay N Carpp, Barton F Haynes, Hua-Xin Liao, David C Montefiori, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Jaranit Kaewkungwal, Gustavo H Kijak, Sodsai Tovanabutra, Donald P Francis, Carter Lee, Faruk Sinangil, Phillip W Berman, Nakorn Premsri, Prayura Kunasol, Robert J O'Connell, Nelson L Michael, Merlin L Robb, Rhoda Morrow, Lawrence Corey, Jerome H Kim
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0176428 (2017)
BACKGROUND:In the HIV-1 vaccine trial RV144, ALVAC-HIV prime with an AIDSVAX® B/E boost reduced HIV-1 acquisition by 31% at 42 months post first vaccination. The bivalent AIDSVAX® B/E vaccine contains two gp120 envelope glycoproteins, one from the
Externí odkaz:
https://doaj.org/article/749ab0ed603a4682a6678cef9d673819
Autor:
Jaranit Kaewkungwal, Saintedym Wills, Carlos A. DiazGranados, Merlin L. Robb, Poonam Pegu, James Tartaglia, Rv Study Team, Allan C. deCamp, Nakorn Premsri, Alexandra Schuetz, Sanjay Garunathan, Michael A. Eller, Robert J. O'Connell, Nicos Karasavvas, Nathan Vandergrift, Sorachai Nitayaphan, Faruk Sinangil, Jean-Louis Excler, Punnee Pitisuttithum, Chitraporn Karnasuta, Nelson L. Michael, Silvia Ratto-Kim, Georgia D. Tomaras, Sanjay Phogat, Jerome H. Kim, Supachai Rerks-Ngarm, Sheetal Sawant, David C. Montefiori, Prayura Kunasol, Viseth Ngauy, Sandhya Vasan, Peter Dawson
Publikováno v:
The Journal of Infectious Diseases. 215:1255-1263
Background The RV144 ALVAC-HIV prime, AIDSVAX B/E boost afforded 60% efficacy against human immunodeficiency virus (HIV) acquisition at 1 year, waning to 31.2% after 3.5 years. We hypothesized that additional vaccinations might augment immune correla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bf9e33d8eb074748379853a436e1b0d
https://doi.org/10.1093/infdis/jix099
https://doi.org/10.1093/infdis/jix099
Publikováno v:
AIDS. 15:S73-S79
In this paper we review current guidelines in assuring the rights of study participants and review the experiences in three randomized placebo-controlled double-blinded clinical trials of potential new HIV prevention technologies. The education of st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55e77bd88b8a48c3c2a081840329c45b
https://doi.org/10.1097/00002030-200100005-00010
https://doi.org/10.1097/00002030-200100005-00010
Autor:
Mike W. Benenson, Sorachai Nitayaphan, Prayura Kunasol, Chirasak Khamboonruang, Punnee Pitisuttithum, Yupa Sabmee, Pravan Suntharasamai, Jerome H. Kim, S. Pungpak, Robert J. O'Connell, Jaranit Kaewkungwal, Valai Bussaratid, Prasert Thongcharoen, Jittima Dhitavat, Patricia Morgan, Wirach Maek-a-nantawat, S. Vanijanonta, Rungrawee Pawarana, Supachai Rerks-Ngarm
Publikováno v:
AIDS research and human retroviruses. 29(11)
To assess qualities and outcomes of women participating in a large, community-based HIV vaccine trial, the present study was conducted among female participants of the RV 144 prime-boost trial in Thailand from 2003 to 2009. Qualities of participation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8a728eb94fef82a5c6861e7bebd96ba
https://pubmed.ncbi.nlm.nih.gov/23343395
https://pubmed.ncbi.nlm.nih.gov/23343395
Autor:
Chirapa Eamsila, Jorge Flores, Donald P. Francis, Rapee Trichavaroj, Nampueng Churikanont, Chawetsan Namwat, Robert Paris, Sorachai Nitayaphan, Jaranit Kaewkungkal, Elizabeth Adams, Jim Tartaglia, Peter B. Gilbert, Merlin L. Robb, Mark de Souza, Chureeratana Bowonwatanuwong, Prasert Thongcharoen, Viseth Ngauy, Sanjay Gurunathan, Charla Andrews, Jerome H. Kim, Supamit Chunsutthiwat, Prayura Kunasol, Nakorn Premsri, Shuying S. Li, Nelson L. Michael, Robert J. O'Connell, Supachai Rerks-Ngarm
Publikováno v:
The Journal of infectious diseases. 207(8)
Background The Thai Phase III Trial of ALVAC-HIV and AIDSVAX B/E showed an estimated vaccine efficacy (VE) of 31% to prevent acquisition of human immunodeficiency virus (HIV). Here we evaluated the effect of vaccination on disease progression after i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0691d67ac0e6639bcdd873bf992c0712
https://pubmed.ncbi.nlm.nih.gov/22829649
https://pubmed.ncbi.nlm.nih.gov/22829649
Autor:
Michael Benenson, Sanjay Gurunathan, Don Stablein, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Prasert Thongcharoen, Jerome H. Kim, Sorachai Nitayaphan, Elizabeth Adams, Merlin L. Robb, Chirasak Khamboonruang, Jim Tartaglia, Peter B. Gilbert, Jaranit Kaewkungwal, Patricia Morgan, Donald P. Francis, Joseph Chiu, Prayura Kunasol, Nelson L. Michael, Robert Paris
Publikováno v:
The Lancet. Infectious diseases. 12(7)
Summary Background The Thai phase 3 HIV vaccine trial RV 144 showed modest efficacy of a vaccine against HIV acquisition. Baseline variables of age, sex, marital status, and risk did not modify vaccine efficacy. We did a post-hoc analysis of the tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93694e58ebb2a54aa9495c8518ad4d26
https://pubmed.ncbi.nlm.nih.gov/22652343
https://pubmed.ncbi.nlm.nih.gov/22652343
Autor:
Supachai, Rerks-Ngarm, Punnee, Pitisuttithum, Sorachai, Nitayaphan, Jaranit, Kaewkungwal, Joseph, Chiu, Robert, Paris, Nakorn, Premsri, Chawetsan, Namwat, Mark, de Souza, Elizabeth, Adams, Michael, Benenson, Sanjay, Gurunathan, Jim, Tartaglia, John G, McNeil, Donald P, Francis, Donald, Stablein, Deborah L, Birx, Supamit, Chunsuttiwat, Chirasak, Khamboonruang, Prasert, Thongcharoen, Merlin L, Robb, Nelson L, Michael, Prayura, Kunasol, Jerome H, Kim, J, Berenberg
Publikováno v:
The New England journal of medicine. 361(23)
The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control.In a community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial, we evaluated four
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c868c2f9691aace2a4de971ec6e4576
https://pubmed.ncbi.nlm.nih.gov/29493606
https://pubmed.ncbi.nlm.nih.gov/29493606
Autor:
Chirasak Khamboonruang, Prayura Kunasol, Supachai Rerks-Ngarm, Arthur Brown, Prasert Thongcharoen
Publikováno v:
AIDS (London, England). 20(11)
The first case of AIDS in Thailand was reported in September 1984. The number of newly reported AIDS cases increased every year peaking in 1998 with 27 528 cases. As of 31 December 2001 the year of the decision to conduct a phase III vaccine trial th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0858672591a585bfff3d5c0ac05abc0f
https://pubmed.ncbi.nlm.nih.gov/16847401
https://pubmed.ncbi.nlm.nih.gov/16847401
Autor:
Malcolm Guiver, Prayura Kunasol, Sophie Treleaven, Mark C. Steinhoff, Charung Muangchana, Alan Brooks, Beverley-Ann Biggs, James E. Maynard, Sirisak Warintrawat, Surang Dejsirilert, Damien Jolley, Supamit Chunsuttiwat, Supachai Rerks-Ngarm
Publikováno v:
Vaccine. 22(8)
There are limited prospective data for Haemophilus influenzae type b (Hib) disease in Asia, where some countries are considering vaccine introduction. A prospective population-based study was conducted to measure the incidence of Hib meningitis in ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b7d86ff21f9965186f162346d61e5a3
https://pubmed.ncbi.nlm.nih.gov/16171904
https://pubmed.ncbi.nlm.nih.gov/16171904
Publikováno v:
The Lancet. 344:243-245
Summary The Thai government began an HIV-control programme in 1989. The programme had the following parts: the government bought and distributed sufficient condoms to protect much of the commercial sex in the country; sanctions were brought against c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::461ef91804a48b053850c5297bf39c86
https://doi.org/10.1016/s0140-6736(94)93004-x
https://doi.org/10.1016/s0140-6736(94)93004-x